ARRIVENT BIOPHARMA INC
AVBP
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
ArriVent BioPharma develops precision oncology therapeutics targeting EGFR mutations in non-small cell lung cancer. Its lead candidate firmonertinib is an oral, brain-penetrant, mutation-selective EGFR inhibitor already approved in China and granted FDA Breakthrough Therapy Designation for first-line treatment of EGFR exon 20 insertion mutant NSCLC. The pivotal Phase 3 FURVENT trial completed enrollment in early 2025 with topline data projected for early 2026, and the ALPACCA Phase 3 trial began enrolling for EGFR PACC mutant NSCLC. ArriVent also advances ALX2004, a dual-target MUC16/NaPi2b antibody-drug conjugate. Preclinical animal testing is central to the pipeline: firmonertinib demonstrated enhanced binding and activity against EGFR mutant proteins in NSCLC animal models, with new preclinical posters presented at the 2026 AACR Annual Meeting.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.